IFM Investors Pty Ltd Increases Position in Gilead Sciences, Inc. $GILD

IFM Investors Pty Ltd increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 256,664 shares of the biopharmaceutical company’s stock after acquiring an additional 2,635 shares during the period. IFM Investors Pty Ltd’s holdings in Gilead Sciences were worth $28,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management boosted its holdings in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors raised its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its position in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the transaction, the insider directly owned 113,193 shares in the company, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares of the company’s stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,390,030. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 1.2%

GILD opened at $113.62 on Friday. The firm has a market capitalization of $140.98 billion, a price-to-earnings ratio of 22.63, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. The company’s 50 day simple moving average is $114.01 and its two-hundred day simple moving average is $110.07. Gilead Sciences, Inc. has a 1-year low of $81.83 and a 1-year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several analyst reports. UBS Group boosted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Royal Bank Of Canada increased their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research report on Friday, August 8th. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.